|
|
|
|
Vol. 56, Issue 1, 141-146, July 1999
Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique, Unité Propre de Recherche 9062, Toulouse, France (P.F., Y.C., C.M., P.C., B.S.); Unité Propre de l'Enseignement Supérieur, Pr Eschwege, Laboratoire de Radiobiologie, Institut Gustave Roussy, Villejuif, France (E.M., J.B.); and Unité Mixte de Recherche 1599 Centre National de la Recherche Scientifique, Institut Gustave Roussy, Villejuif, France (N.F.)
| |
Summary |
|---|
|
|
|---|
cis-Dichlorodiammineplatinum(II) (CDDP; cisplatin)
is commonly used in combination with ionizing radiation (IR) in the
treatment of various malignancies. In vitro, many observations suggest
that acquisition of CDDP resistance in cell lines confers
cross-resistance to IR, but the molecular mechanisms involved have not
been well documented yet. We report here the selection and
characterization of a murine CDDP-resistant L1210 cell line (L1210/3R)
that exhibits cross-resistance to IR because of an increased capacity
to repair double-strand breaks compared with parental cells (L1210/P).
In resistant cells, electrophoretic mobility shift assays revealed an
increased DNA-end binding activity that could be ascribed, by
supershifting the retardation complexes with antibodies, to the
autoantigen Ku. The heterodimeric Ku protein, composed of 86-kDa (Ku80)
and 70-kDa (Ku70) subunits, is the DNA-targeting component of
DNA-dependent protein kinase (DNA-PK), which plays a critical role in
mammalian DNA double-strand breaks repair. The increased Ku-binding
activity in resistant cells was associated with an overexpression
affecting specifically the Ku80 subunit. These data strongly suggest
that the increase in Ku activity is responsible for the phenotype of
cross-resistance to IR. In addition, these observations, along with
previous results from DNA-PK
mutant cells, provide
evidence in favor of a role of Ku/DNA-PK in resistance to CDDP. These
results suggest that Ku activity may be an important molecular target
in cancer therapy at the crossroad between cellular responses to CDDP
and IR.
| |
Introduction |
|---|
|
|
|---|
cis-Dichlorodiammineplatinum(II)
(CDDP) is commonly used in combination with ionizing radiation (IR) in
the treatment of various malignancies, such as head and neck tumors.
Significant correlations between the response to CDDP and the
subsequent response to IR have been reported in patients receiving
CDDP-based regimens followed by radiotherapy (reviewed in Coughlin and
Richmond, 1989
). In vitro, many observations suggest that acquisition
of CDDP resistance in cell lines often confers cross-resistance to IR
(Wallner and Li, 1987
; De Pooter et al., 1991
; Hill, 1991
).
Interestingly, De Pooter et al. (1991)
demonstrated that although
resistance to CDDP might have unfavorable consequences for IR, the
reverse was not true, because increased sensitivity to CDDP was found when resistance against IR was induced in the same cells. Finally, significant cross-resistance between IR and CDDP was shown in one
series of early passage human tumor cell lines (Schwartz et al., 1988
).
However, molecular mechanisms operating in cancer cells resistant to
both treatments have not been well documented so far.
In this respect, the DNA-dependent protein kinase (DNA-PK) is of
particular interest because several studies demonstrated that this
protein is involved in the cell responses to both IR and CDDP. DNA-PK
is a nuclear serine/threonine protein kinase composed of a large,
460-kDa catalytic subunit (DNA-PKcs), and a DNA binding subunit, the Ku
autoantigen (a dimer of the Ku70 and Ku80 proteins) (Gottlieb and
Jackson, 1993
). Ku binds to DNA double-strand ends and other
discontinuities in the DNA (Blier et al., 1993
; Falzon et al., 1993
)
and recruits the catalytic subunit of the complex (Gottlieb and
Jackson, 1993
). The active DNA-PK complex then acquires the capacity,
at least in vitro, to phosphorylate many DNA-bound proteins in the
vicinity (for review, see Anderson et al., 1995
). A large number of
studies demonstrated that rodent cell lines mutated for either
component of DNA-PK are hypersensitive to ionizing radiation (IR)
because of a decreased ability to repair DNA double-strand breaks
(DSBs) (for review, see Jeggo, 1997
). Further evidence that DNA-PK is involved in DNA DSB repair is provided by the hypersensitivity to IR of
knock-out mice for Ku80 (Nussenzweig et al., 1996
; Zhu et al., 1996
) or
Ku70 (Ouyang et al., 1997
). Thus, these experiments clearly identified
DNA-PK as a crucial component of a nonhomologous mechanism of DSB
rejoining in mammalian cells (for review, see Jeggo, 1997
). In
addition, these mutant cells also exhibit significant hypersensitivity
to CDDP and to the nitrogen mustards (NMs) melphalan and
mechlorethamine (Caldecott and Jeggo, 1991
; Tanaka et al., 1993
). The
hypersensitivity to CDDP of a rodent mutant cell line that lacks the
Ku80 subunit seems to be related to the DNA-PK defect, because upon
stable transfection with the human Ku80 gene (XRCC5),
enhanced resistance to CDDP was regained together with bleomycin
resistance and Ku DNA end-binding activity (Muller et al., 1998a
). In
contrast to IR, the mechanism(s) by which DNA-PK participates in the
cellular response to CDDP remains only partially understood. We have
recently demonstrated a role for DNA-PK as a positive modulator in vivo
of the nucleotide excision repair (NER) process, the main pathway
involved in the repair of CDDP intrastrand cross-links (Muller et
al., 1998a
). In addition, it has been suggested that DNA-PK might
participate in the repair of interstrand cross-links (ICL) that are
removed from DNA in mammalian cells by the combined actions of NER and
recombination processes (Caldecott and Jeggo, 1991
; Chaney and Sancar,
1996
; Bessho et al., 1997
). Thus, DNA-PK seems to be involved in the cellular response to IR and CDDP through DNA-repair-mediated mechanism(s).
The aim of the present study was to determine whether regulation of Ku/DNA-PK activity might be involved in the acquisition of cellular resistance to IR after CDDP exposure. To test this hypothesis, we have selected a CDDP-resistant L1210 cell line that displays significant cross-resistance to IR. We demonstrated here that this phenotype is associated with enhanced DNA-end binding (DEB) activity involving the Ku heterodimer.
| |
Materials and Methods |
|---|
|
|
|---|
Cell Lines and Culture.
The CDDP-resistant L1210/R cell line
was obtained by chronic exposure of L1210/P (a gift from Dr. S. Cros,
Institut de Pharmacologie et de Biologie Structurale, Toulouse,
France) to stepwise increasing concentrations of CDDP (a kind gift of
Roger Bellon, groupe Rhône-Poulenc Rorer, Montrouge,
France) over a period of 9 months. The resistance phenotype was
stable, even in the absence of CDDP for several months. The HeLa S3
cell line was obtained from the stock of the European Molecular Biology
Laboratories (Heidelberg, Germany). The Chinese hamster ovary (CHO)-AA8
and the corresponding mutant CHO-V3 cell lines were kindly provided by
Dr. G. Whitmore (Ontario Cancer Institute, Toronto, Ontario,
Canada) (Peterson et al., 1995
). L1210/P, L1210/3R, and HeLa cells were
cultured in suspension in RPMI 1640 (Gibco BRL) supplemented with 10%
fetal calf serum, 2 mM glutamine, penicillin (2 × 105 U/liter), and streptomycin (50 mg/liter). All
cells were maintained at 37°C in a 5% CO2
humidified atmosphere.
Cell Treatment and Cytotoxicity Studies.
Cellular
CDDP, mechlorethamine, and melphalan toxicities were determined by the
colorimetric 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) metabolic dye assay (Sigma, St. Louis, MO) as
described elsewhere (Canitrot et al., 1997
). Ionizing radiation
toxicity was determined by clonogenic assay as follows: A total of
103 cells/ml was resuspended in RPMI medium
supplemented with 10% fetal calf serum, 0.9% methylcellulose (Stem
Cell Technologies, Vancouver, British Columbia, Canada; TEBU).
Five hundred cells were seeded into 35-mm Petri dishes and irradiated
at 1 Gy/min with a cobalt source (Centre d'Études et de
Recherche de Toulouse-l'Office National d'Études et de
Recherches Aérospatiales et de l'Espace, Toulouse, France). The
dishes were then incubated at 37°C in a humidified 5%
CO2 atmosphere for 8 days. Colonies of more than 50 cells were counted by microscope. IC50 values
represent the drug concentration or the
-ray dose leading to 50%
cell survival.
Cell Extracts.
Whole-cell protein extracts were prepared
according to Manley et al. (1983)
with the minor modifications
described previously (Wood et al., 1988
). Protein concentrations were
determined by the method of Bradford (1976)
using the Bio-Rad protein
assay dye (Bio-Rad Labs., Hercules, CA).
Band Shift Assay.
The probe was prepared as follows: an
aliquot of a 123-basepair DNA ladder (Gibco BRL, Gaithersburg, MD) was
digested with AvaI (Gibco BRL) to generate 123-basepair
monomers. After purification from agarose gel, fragments were
end-labeled with [
-32P]dCTP using DNA
polymerase I Klenow fragment (Gibco BRL). End-labeled probes were
separated from unincorporated nucleotides by chromatography through
Sephadex G-50 (Sigma). The band-shift assay was performed as described
previously (Zhang and Yaneva, 1992
). Briefly, radiolabeled DNA (4 ng,
100,000 cpm) was incubated with extracts (3 µg) in 20 µl of binding
buffer (20 mM Tris · HCl, pH 7.5, 100 mM NaCl, 1 mM dithiothreitol,
5 mM MgCl2, 0.2 mM EGTA, and 5% glycerol) in the
presence of 1 µg of circular plasmid as a nonspecific competitor at
30°C for 30 min. The samples were electrophoresed on a 5%
polyacrylamide gel at 4°C for 2 h at 100 V. The gel was dried on
Whatman paper and autoradiographed with Kodak X-OMAT films (Eastman
Kodak, Rochester, NY). The regions of the gel containing the free probe
and the retardation complexes were quantified by scintillation
counting. The supershift experiments were performed as described
previously (Muller et al., 1998c
). The antibodies used were purified on
protein A sepharose from human autoimmune antisera Hi (kindly provided by Dr. Y. Takeda, Medical College of Georgia, Augusta, GA) and AF (a generous gift from Dr. E. M. Tan, Scripps Research
Institute, La Jolla, CA). Human sera Hi and AF specifically
recognize Ku70 alone or Ku70 and Ku80, respectively (Francoeur et al.,
1986
). The human serum Sa that contains anti-ribonucleoprotein
antibodies (provided by Dr Y. Takeda, Augusta, GA) was used as a
control. Monoclonal 30F3 antibody was provided by Dr. M. Le Romancer
(Institut National de la Santé et de la Recherche Médicale
U10, Hopital Bichat, Paris, France)
Western Blot Analysis. Protein extracts from rodent cells (100 µg) and HeLa cells (20 µg) as a control were resolved by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Amersham, Arlington Heights, IL) by semidry electroblotting. After checking for homogeneous transfer by Red Ponceau staining, the membrane was blocked with Tris-buffered saline/Tween 20 (TBST)-milk (20 mM Tris · HCl, pH 7.6, 137 mM NaCl, 0.2% Tween, and 5% nonfat dry milk). The membrane was hybridized overnight at 4°C with TBST-milk containing either 500-fold diluted AF human antiserum, 5,000-fold diluted 18.2 monoclonal anti-DNA-PKcs antibody (a generous gift from Prof. T. H. Carter, St. John's University, New York, NY) or 10,000-fold diluted monoclonal antiactin antibody (Interchim, Montlucon, France). The membrane was then rinsed with TBST at room temperature and hybridized with TBST-milk containing peroxidase-conjugated goat antihuman antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). The membrane was then extensively washed with TBST and developed for antibody binding by the enhanced chemiluminescence procedure carried out according to the manufacturer's recommendations (Du Pont-NEN, Boston, MA).
DNA-PK Activity Assays.
Kinase assays were performed as
described previously (Finnie et al., 1995
) with some modifications
(Muller et al., 1998a
). Each sample was assayed in the presence of
either DNA-PK-specific peptide substrate (SQE peptide:
EPPLSQEAFADLLKK) or a negative control peptide (SEQ peptide:
EPPLSEQAFADLLKK). DNA-PK activity was expressed in counts
per minute incorporated in the SQE peptide or in the SEQ peptide for a
given extract.
Kinetics of DSB Repair.
Kinetics of DSB repair assay was
performed using pulsed-field electrophoresis (CHEF DRIII; BioRad) in
the megabase size region as reported previously (Foray et al., 1997
).
The repair kinetics data were presented as the percentage of fraction
of activity released (FAR) remaining at indicated times, as previously
described (Foray et al., 1997
). The FAR data were fitted to the
variable repair half-time (VHRT) model (Foray et al., 1996
)
| |
Results |
|---|
|
|
|---|
In Vitro Drug and
-Ray Sensitivity of L1210 Cell Lines.
The
L1210 cell line (L1210/P) was adapted in vitro to stepwise increasing
concentrations of CDDP for about 1 year, leading to a subline termed
L1210/3R, which was resistant to 3 µg/ml CDDP. The resistance was
stable, even in the absence of CDDP for several months (data not
shown). As judged by the IC50 value obtained from
MTT metabolic dye assays (Table 1),
L1210/3R cells were 16-fold resistant to CDDP compared with the L1210/P
cell line and exhibited cross-resistance to the DNA cross-linking
agents mechlorethamine and melphalan (3.6- and 2.3-fold, respectively; see Table 1). We then investigated whether L1210/3R cells were cross-resistant to IR. As shown in Fig.
1, L1210/3R were resistant to IR by a
factor of 2-fold compared with L1210/P cells (see Table 1 for
IC50). Again, this resistance was stable, even in
the absence of CDDP for several months (data not shown). In contrast,
L1210/3R cells were not cross-resistant to the monofunctional
alkylating agent
N-methyl-N'-nitro-N-nitrosoguanidine,
which induces DNA damage mainly processed by the base excision-repair
pathway (Table 1).
|
|
DSB Repair Kinetics.
Repair of DSBs has been shown to play a
key role in the radiosensitivity of mammalian cells. We investigated
whether, compared with L1210/P cells, the resistance of L1210/3R cells
to IR was related to an increased capacity to repair DSBs. The kinetics of DSB repair was studied by measuring the percent of FAR remaining as
a function of the time, after an exposure to 30 Gy. As shown in Fig.
2, the capacity to repair DSBs was more
rapid in the resistant L1210/3R than in the parental L1210/P cells.
After the irradiation, the percentage of FAR remaining dropped to 50%
in 30 min for the L1210/3R cells, whereas a longer time (60 min) was
necessary to observe the same effect in the L1210/P cells. Because
Ku/DNA-PK represents one of the major protein complexes involved in
DSBs repair in mammalian cells, this result raises the possibility of
an involvement of this complex in the cross-resistance phenotype of
L1210/3R cells to IR.
|
Activity and Expression of the Ku/DNA-PKcs.
We first
investigated the kinase activity of the whole DNA-PK complex in L1210/P
and L1210/3R cells as well as in CHO-AA8 and CHO-V3 as control. As
shown in Fig. 3A, the DNA-PK activity was
comparable in the two parental cell lines L1210/P and CHO-AA8, although, as expected, it was absent in the DNA-PKcs mutant cell line
(CHO-V3). No significant differences in DNA-PK activity were observed
between protein extracts from resistant and sensitive L1210 cells.
Accordingly, DNA-PKcs was expressed at comparable levels in CHO-AA8,
L1210/P, and L1210/R cells and was absent in CHO-V3 cells (Fig. 3B).
The activity of the regulatory subunit of DNA-PK, the Ku heterodimer,
was then assessed. Ku DEB activity can be detected easily by using
double-stranded DNA fragments in an electrophoretic mobility shift
assay (EMSA) (Zhang and Yaneva, 1992
). Independent cell extracts were
used; a representative experiment is shown in Fig.
4A. The DEB activity was increased by 5- to 6-fold in cell extracts from resistant cells compared with extracts
from the parental L1210/P cells. As described previously (Zhang and Yaneva, 1992
; Falzon et al., 1993
), Ku was considered the most likely
causal protein for the formation of these DEB complexes. To verify this
hypothesis, we evaluated the presence or absence of Ku70 and Ku80
proteins in the DEB complexes, by using various antibodies directed
against these proteins in EMSA supershift experiments. Antibodies
purified from two independent human sera able to recognize Ku70 (Fig.
4B, lane S1) or both Ku70/80 subunits (Fig. 4B, lane S2) were used. In
the presence of these antibodies, DEB complexes were completely
supershifted and retarded in the gel, as shown in Fig. 4B. Moreover,
the S0 control antiserum (which contained anti-ribonucleoprotein
autoantibodies) has no effect on the migration of the DEB complexes
(lane S0). Thus, this set of experiments indicates that the DEB
complexes corresponded to the Ku heterodimer.
|
|
| |
Discussion |
|---|
|
|
|---|
Molecular mechanisms operating in cancer cells resistant to IR after CDDP exposure have not been well documented thus far. In the present article, we report that the Ku antigen is likely to play a role in this phenotype.
The L1210/3R cells exhibited a stable cross-resistance to IR because of
an increased capacity to repair DSBs compared with parental cells.
According to the literature, the increase in Ku DEB activity in
resistant cells is likely to explain this phenotype. Indeed, the
extreme radiosensitivity and DSB repair deficiency found in Ku80
(Smider et al., 1994
; Taccioli et al., 1994
) or Ku70 (Lee et al., 1995
)
rodent mutant cell lines, as well as in the Ku80 (Nussenzweig et al.,
1996
; Zhu et al., 1996
) or Ku70 (Ouyang et al., 1997
) knock-out mice,
clearly identify Ku as a major component of the DSB's repair apparatus
in mammalian cells. In our model, the enhanced Ku DEB activity in
L1210/3R cells was not associated with an increase in kinase activity
of the whole DNA-PK complex (Fig. 3A). Thus, our results suggest that
the level of expression of DNA-PKcs, which is not modified in resistant cells (Fig. 3B), is the limiting component of the holoenzyme activity. Recent evidence suggests that enhanced Ku DEB activity alone may account for the observed increase in DSB repair. Indeed, it has been
reported that Ku, independently of DNA-PKcs, plays a direct role in the
repair of DSBs by stimulating DEB by mammalian ligases (Ramsden and
Gellert, 1998
). First, we investigated the potential inducibility of
Ku80 expression by using CDDP treatment after an incubation of
sensitive L1210 cells with the drug (1 h at doses corresponding to the
IC50 and IC90 values). No
change in Ku80 expression was noticed until 48 h postincubation
time as determined by Western blot analysis and EMSA (data not shown).
Thus, the increased Ku DEB activity of the resistant cells seemed
dependent on a stable overexpression of the Ku80 protein. It has been
reported previously that the individual Ku subunits are degraded when
not dimerized, because the Ku 70 protein was undetectable in Ku80 mutants (Satoh et al., 1995
; Singleton et al., 1997
). In addition, both
subunits need to be present at stoichiometric levels to form stable
complexes in an EMSA (Wu and Lieber, 1996
). The differential signal
obtained by Western blotting experiments between Ku70 and Ku80 is
probably caused by the respective recognition property of the primary
antibodies used. However, additional mechanisms, such as
post-translational modifications affecting Ku affinity for DNA termini,
have been reported (Quinn et al., 1992
). We cannot exclude that an
additional post-translational modification of the Ku70 subunit
participates in the increase in Ku DEB activity.
Our data show for the first time that an increase in Ku DEB activity is
associated with a stable phenotype of resistance to acute
-ray
radiation, with this increase in Ku DEB activity being observed after
CDDP selection. An increasing body of evidence from our laboratory and
others suggest that the increase in Ku activity is likely to be
directly involved in CDDP resistance rather than reflecting random
genetic changes occurring after exposure to CDDP over 9 months. Indeed,
it is now clearly established that rodent cells mutated for either
component of DNA-PK, in addition to being hypersensitive to IR, also
exhibit sensitivity to CDDP (Caldecott and Jeggo, 1991
; Tanaka et al.,
1993
; Muller et al., 1998a
). Moreover, resistance to CDDP was restored
by transfection of a functional human Ku80 (XRCC5) gene in a
Ku80 minus cell line (Muller et al., 1998a
). At the molecular level,
the role of Ku/DNA-PK in CDDP resistance can be considered to involve
different, nonexclusive DNA-repair-mediated mechanisms. We have
recently demonstrated a regulatory function of Ku/DNA-PK in the NER
process in vivo but not in vitro (Muller et al., 1998a
). Accordingly,
the increase in Ku DEB activity might facilitate the NER activity in
L1210/3R cells and therefore contribute to CDDP resistance. In fact,
the resistant cells exhibit enhanced NER activity as measured with an
in vitro cell-free repair assay (F. Frit, P.C., J. M. Barret and
B.S., unpublished observations). Modulation of Ku levels of expression
in vivo, with either dominant negative constructs or antisense
strategies, will be necessary to demonstrate the facilitating effect of
Ku on NER activity in L1210/3R cells. Such approaches are currently
under investigation in our laboratory. In addition, an increase in Ku
DEB activity might also enhance the repair of ICL, because this subset
of adducts is believed to be processed by mechanisms requiring both
excision and recombination steps (Chaney and Sancar et al., 1996
;
Bessho et al., 1997
). In accordance, the DNA-PK deficient cells are
hypersensitive to the NMs melphalan and mechlorethamine (Caldecott and
Jeggo, 1991
; Tanaka et al., 1993
). The ICL of DNA is generally thought
to be responsible for the cytotoxicity of these drugs. Interestingly,
the L1210/3R cells also exhibited significant cross-resistance to these
two drugs (Table 1). In addition to the well described role of DNA-PK
in the cellular response to CDDP, there are further arguments
suggesting that an increase in Ku DEB activity is probably not an
additional, independent event occurring during the selection of the
resistant cell line. First, we observed an increase in Ku DEB activity
in another CDDP-resistant L1210 cell line that has been selected in
vivo in tumor-bearing mice (Geran et al., 1972
; Calsou et al., 1993
;
our data not shown). However, we could not obtain further evidence that this cell line exhibited cross-resistance to IR and
increased DSB repair activity, because adaptation to in vitro growth
conditions resulted in rapid loss of the resistance phenotype (Geran et
al., 1972
; our data not shown). Second, we have reported previously that Ku DEB activity was increased in lymphocytes from patients that exhibited a chronic lymphocytic leukemia resistant to NMs
compared with sensitive ones (Muller and Salles, 1997
; Christodoulopoulos et al., 1998
; Muller et al., 1998b
). Interestingly, these resistant samples also exhibited significant cross-resistance to
the radiomimetic agent, neocarzinostatin (Muller and Salles, 1997
).
Thus, along with the present study, these results suggest that the
increase of Ku DEB activity might be an important feature in cancer
cells resistant to IR after CDDP or NM selection and might participate
in the emergence of cells resistant to these two chemotherapeutic
agents. An increase in Ku expression and activity has been observed in
two model systems (rodent cells and human primary tumor cells)
exhibiting a basal level of Ku expression lower than the level usually
observed in established human cell lines (Muller and Salles,
1997
; Muller et al., 1998b
; present study). Thus, one may
suppose that an increase in Ku expression associated with CDDP
resistance would not be observed in cells exhibiting constitutively
very high basal levels of Ku expression. According to this hypothesis,
the only study that has examined the expression of Ku 70 and Ku 80 in a
human CDDP-resistant ovarian cell line revealed no change in comparison
with the CDDP-sensitive parental cell line (Henkels and Turchi, 1997
).
The relation between CDDP and radiation resistance in vitro, as demonstrated in the present study, is particularly interesting, given the results of clinical trials with CDDP regimens and radiotherapy. Consequently, it would be of great interest to investigate the Ku binding activity in clinical samples resistant to CDDP, particularly when associated with radioresistance. Such studies would be of great clinical interest because, once the role of Ku is demonstrated, modulation of its activity by antisense or dominant-negative constructs might contribute to improving the efficacy of cancer therapy.
| |
Footnotes |
|---|
Received October 9, 1998; Accepted March 25, 1999
This work was supported by the Association pour la Recherche contre le Cancer and the Ligue Nationale contre le Cancer.
Send reprint requests to: Dr. Bernard Salles, Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique, Unité Propre de Recherche 9062, 205 route de Narbonne, 31077 Toulouse Cedex, France. E-mail: salles{at}ipbs.fr
| |
Abbreviations |
|---|
CDDP, cis-dichlorodiammineplatinum(II) (cisplatin); DNA-PK, DNA-dependent protein kinase; DNA-PKcs, DNA-dependent protein kinase catalytic subunit; IR, ionizing radiation; DSB, double-strand break; NM, nitrogen mustard; NER, nucleotide excision repair; ICL, interstrand cross links or linking; DEB, DNA-end binding; CHO, Chinese hamster ovary; TBST, Tris-buffered saline/Tween 20; FAR, fraction of activity released; EMSA, electrophoretic mobility shift assay.
| |
References |
|---|
|
|
|---|
-ray-sensitive hamster mutants to cross-linking agents.
Mutat Res
255:
111-121[Medline].This article has been cited by other articles:
![]() |
S. Yotsumoto, K. Saegusa, and Y. Aramaki Endosomal Translocation of CpG-Oligodeoxynucleotides Inhibits DNA-PKcs-Dependent IL-10 Production in Macrophages J. Immunol., January 15, 2008; 180(2): 809 - 816. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Napieralski, K. Ott, M. Kremer, K. Specht, H. Vogelsang, K. Becker, M. Muller, F. Lordick, U. Fink, J. Rudiger Siewert, et al. Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer Patients Clin. Cancer Res., April 15, 2005; 11(8): 3025 - 3031. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Veuger, N. J. Curtin, C. J. Richardson, G. C. M. Smith, and B. W. Durkacz Radiosensitization and DNA Repair Inhibition by the Combined Use of Novel Inhibitors of DNA-dependent Protein Kinase and Poly(ADP-Ribose) Polymerase-1 Cancer Res., September 15, 2003; 63(18): 6008 - 6015. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Kim, S.-J. Park, and S.-H. Lee A Targeted Inhibition of DNA-Dependent Protein Kinase Sensitizes Breast Cancer Cells Following Ionizing Radiation J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 753 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Belenkov, J.-P. Paiement, L. C. Panasci, B. P. Monia, and T. Y. K. Chow An Antisense Oligonucleotide Targeted to Human Ku86 Messenger RNA Sensitizes M059K Malignant Glioma Cells to Ionizing Radiation, Bleomycin, and Etoposide but not DNA Cross-Linking Agents Cancer Res., October 15, 2002; 62(20): 5888 - 5896. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-T. Tai, G. Teoh, B. Lin, F. E. Davies, D. Chauhan, S. P. Treon, N. Raje, T. Hideshima, Y. Shima, K. Podar, et al. Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage J. Immunol., December 1, 2000; 165(11): 6347 - 6355. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||